FI946201A0 - Självstabiliserade oligonukleotider som terapeutiska medel - Google Patents

Självstabiliserade oligonukleotider som terapeutiska medel

Info

Publication number
FI946201A0
FI946201A0 FI946201A FI946201A FI946201A0 FI 946201 A0 FI946201 A0 FI 946201A0 FI 946201 A FI946201 A FI 946201A FI 946201 A FI946201 A FI 946201A FI 946201 A0 FI946201 A0 FI 946201A0
Authority
FI
Finland
Prior art keywords
self
therapeutic agents
stabilized
stabilized oligonucleotides
oligonucleotides
Prior art date
Application number
FI946201A
Other languages
English (en)
Finnish (fi)
Other versions
FI946201A (sv
Inventor
Sudhir Agrawal
Jin-Yan Tang
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Publication of FI946201A0 publication Critical patent/FI946201A0/sv
Publication of FI946201A publication Critical patent/FI946201A/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
FI946201A 1992-07-02 1994-12-30 Självstabiliserade oligonukleotider som terapeutiska medel FI946201A (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90906992A 1992-07-02 1992-07-02
PCT/US1993/006326 WO1994001550A1 (en) 1992-07-02 1993-07-02 Self-stabilized oligonucleotides as therapeutic agents

Publications (2)

Publication Number Publication Date
FI946201A0 true FI946201A0 (sv) 1994-12-30
FI946201A FI946201A (sv) 1994-12-30

Family

ID=25426596

Family Applications (1)

Application Number Title Priority Date Filing Date
FI946201A FI946201A (sv) 1992-07-02 1994-12-30 Självstabiliserade oligonukleotider som terapeutiska medel

Country Status (14)

Country Link
EP (1) EP0649467B1 (sv)
JP (1) JPH08501928A (sv)
KR (1) KR950702626A (sv)
AT (1) ATE171210T1 (sv)
AU (1) AU4770093A (sv)
CA (1) CA2139319A1 (sv)
CZ (1) CZ333294A3 (sv)
DE (1) DE69321122D1 (sv)
FI (1) FI946201A (sv)
HU (1) HUT69981A (sv)
NZ (1) NZ255028A (sv)
PL (1) PL172710B1 (sv)
RU (1) RU94046425A (sv)
WO (1) WO1994001550A1 (sv)

Families Citing this family (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2703053B1 (fr) * 1993-03-26 1995-06-16 Genset Sa Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .
WO1995024477A1 (en) * 1994-03-08 1995-09-14 City Of Hope Human papillomavirus targeted ribozymes
US5631148A (en) * 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement
WO2000022114A1 (en) * 1998-10-09 2000-04-20 Ingene, Inc. PRODUCTION OF ssDNA $i(IN VIVO)
US5750674A (en) * 1995-05-23 1998-05-12 Hybridon, Inc. Methods and compounds for the stereoselective enrichment of oligonucleotide diastereomers and oligonucleotides thereby produced
US20050032067A1 (en) * 2002-11-05 2005-02-10 Prakash Thazha P. Non-phosphorous-linked oligomeric compounds and their use in gene modulation
US20050042647A1 (en) * 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US20030044941A1 (en) 1996-06-06 2003-03-06 Crooke Stanley T. Human RNase III and compositions and uses thereof
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7070925B1 (en) * 1996-07-16 2006-07-04 Gen-Probe Incorporated Method for determining the presence of an RNA analyte in a sample using a modified oligonucleotide probe
WO1998003646A1 (en) * 1996-07-22 1998-01-29 Hybridon, Inc. Compositions and methods for treating specific gene expression-related diseases and disorders in humans
DE19631919C2 (de) * 1996-08-07 1998-07-16 Deutsches Krebsforsch Anti-Sinn-RNA mit Sekundärstruktur
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
ES2374290T3 (es) 1998-03-20 2012-02-15 Commonwealth Scientific And Industrial Research Organisation Genes sintéticos y constructos genéticos que comprenden los mismos.
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US8598332B1 (en) * 1998-04-08 2013-12-03 Bayer Cropscience N.V. Methods and means for obtaining modified phenotypes
JP5015373B2 (ja) † 1998-04-08 2012-08-29 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 改良表現型を得るための方法及び手段
US20040214330A1 (en) 1999-04-07 2004-10-28 Waterhouse Peter Michael Methods and means for obtaining modified phenotypes
JP2002518047A (ja) * 1998-06-23 2002-06-25 メディカル リサーチ カウンシル 構造化されたアンチセンス核酸分子
DE69941333D1 (de) 1998-07-02 2009-10-08 Gen Probe Inc Molekulare fackeln
JP2002527061A (ja) * 1998-10-09 2002-08-27 インジーン・インコーポレイテッド ｓｓＤＮＡの酵素的合成
US20060172925A1 (en) * 1998-10-26 2006-08-03 Board Of Regents, The University Of Texas System Thio-siRNA aptamers
CA2348823A1 (en) * 1998-12-02 2000-06-08 I.D.M. Immuno-Designed Molecules New oligomeric conjugates liable to transfer biological molecules into cells
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU2008202208C1 (en) * 1999-01-30 2014-04-24 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a defined gene
FR2790757B1 (fr) 1999-03-09 2003-08-01 Bioalliance Pharma Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
CA2334707A1 (en) * 1999-03-31 2000-10-05 Hybridon, Inc. Pseudo-cyclic oligonucleobases
DE19925073C2 (de) * 1999-06-01 2001-07-19 Stefan Weiss Nucleinsäuremoleküle mit spezifischer Erkennung von nativem PrP·S··c·, Herstellung und Verwendung
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US7419964B2 (en) 1999-09-16 2008-09-02 Cytogenix, Inc. Treatment of HSV-related pathologies using ssDNA
GB9925459D0 (en) * 1999-10-27 1999-12-29 Plant Bioscience Ltd Gene silencing
US8017742B2 (en) * 1999-11-10 2011-09-13 Japan Science And Technology Agency Gene carrier
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10160151A1 (de) * 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
DE60144517D1 (de) * 2000-06-23 2011-06-09 Pioneer Hi Bred Int Rekombinante konstrukte und ihre verwendung bei der reduzierung der genexpression
US20080032942A1 (en) 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20030190635A1 (en) * 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
BRPI0115814B8 (pt) 2000-12-01 2021-05-25 Europaeisches Laboratorium Fuer Molekularbiologie Embl moléculas de rna de filamento duplo, seu método de preparação e composição farmacêutica compreendendo as mesmas
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US7563618B2 (en) * 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
WO2003070888A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
US20050256068A1 (en) 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
WO2003070884A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
WO2003072590A1 (en) * 2002-02-20 2003-09-04 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US8008472B2 (en) 2001-05-29 2011-08-30 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
US7691995B2 (en) 2001-07-12 2010-04-06 University Of Massachusetts In vivo production of small interfering RNAS that mediate gene silencing
DE10133858A1 (de) * 2001-07-12 2003-02-06 Aventis Pharma Gmbh Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
US7612194B2 (en) 2001-07-24 2009-11-03 Monsanto Technology Llc Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof
US8834900B2 (en) 2001-08-17 2014-09-16 University Of Iowa Research Foundation Combination motif immune stimulatory oligonucleotides with improved activity
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
DE10163098B4 (de) * 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
CA2475003A1 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
US8067575B2 (en) 2002-02-20 2011-11-29 Merck, Sharp & Dohme Corp. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US7893248B2 (en) 2002-02-20 2011-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US20090253774A1 (en) 2002-02-20 2009-10-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7928218B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US7928219B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
US7910724B2 (en) 2002-02-20 2011-03-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US7897753B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
EP1432725A4 (en) * 2002-02-20 2005-03-30 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF TELOMERASEGENEXPRESSION WITH SHORT INTERFERING NUCLEIC ACID (SINA)
US8258288B2 (en) 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
JP2005517427A (ja) 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＣ型肝炎ウイルス（ＨＣＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
US20090099117A1 (en) 2002-02-20 2009-04-16 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1472265A4 (en) * 2002-02-20 2005-06-15 Sirna Therapeutics Inc INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENERATED BY RNA INTERFERENCE USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1476459A4 (en) * 2002-02-20 2005-05-25 Sirna Therapeutics Inc INHIBITION OF EXPRESSION OF THE CHROMOSOME TRANSLOCATION GENE AGENT BY RNA INTERFERENCE USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7678897B2 (en) 2002-02-20 2010-03-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US7691999B2 (en) 2002-02-20 2010-04-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20090253773A1 (en) 2002-02-20 2009-10-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20090192105A1 (en) 2002-02-20 2009-07-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
US7897757B2 (en) 2002-02-20 2011-03-01 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US7667029B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US7683165B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US7662952B2 (en) 2002-02-20 2010-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
US7700760B2 (en) 2002-02-20 2010-04-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
AU2003213203A1 (en) * 2002-02-20 2003-09-09 Ribozyme Pharmaceuticals, Incorporated Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways
US7897752B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
US8013143B2 (en) 2002-02-20 2011-09-06 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
US7667030B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US7795422B2 (en) 2002-02-20 2010-09-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US7683166B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US7935812B2 (en) 2002-02-20 2011-05-03 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US7928220B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
JP2005517433A (ja) * 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＴＮＦおよびＴＮＦレセプタースーパーファミリー遺伝子発現のＲＮＡ干渉媒介性阻害
AU2003228667A1 (en) * 2002-04-22 2003-12-19 Sirna Therapeutics Inc. Nucleic acid mediated disruption of hiv fusogenic peptide interactions
AU2012216354B2 (en) * 2002-08-05 2016-01-14 Silence Therapeutics Gmbh Further novel forms of interfering RNA molecules
ES2280826T5 (es) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20050042646A1 (en) 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US8729036B2 (en) 2002-08-07 2014-05-20 University Of Massachusetts Compositions for RNA interference and methods of use thereof
US7956176B2 (en) 2002-09-05 2011-06-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1556402B1 (en) 2002-09-25 2011-06-22 University of Massachusetts In vivo gene silencing by chemically modified and stable sirna
AU2003278957A1 (en) * 2002-09-26 2004-04-23 Amgen, Inc. Modulation of forkhead box o1a expression
CA2749227A1 (en) 2002-10-16 2005-01-13 Board Of Regents Of The University Of Texas System Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
AU2003290597A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
US7078234B2 (en) 2002-12-18 2006-07-18 Monsanto Technology Llc Maize embryo-specific promoter compositions and methods for use thereof
FR2850971B1 (fr) * 2003-02-10 2006-08-11 Aventis Pharma Sa Oligonucleotide antisens inhibant l'expression de la proteine ob-rgrp et procede de detection de composes modifiant l'interaction entre la famille de la proteine ob-rgrp et le recepteur de la leptine
CN1836045B (zh) 2003-03-28 2012-05-09 孟山都技术有限公司 用于早期种子发育的新型植物启动子
US7910523B2 (en) 2003-05-23 2011-03-22 Board Of Regents, The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
US7476729B2 (en) 2003-10-24 2009-01-13 Institut Curie Dbait and uses thereof
EP1526177A1 (en) * 2003-10-24 2005-04-27 Institut Curie Nucleic acids useful for triggering tumor cell lethality
AP2006003611A0 (en) 2003-10-30 2006-06-30 Coley Pharm Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
GB2422607A (en) * 2003-11-10 2006-08-02 Univ Utah Res Found Improved methods and compositions for RNA interference
GB2424887B (en) * 2003-11-26 2008-05-21 Univ Massachusetts Sequence-specific inhibition of small RNA function
US7468431B2 (en) * 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US20060075515A1 (en) * 2004-08-11 2006-04-06 Luethy Michael H Enhanced zein reduction in transgenic corn seed
CA2554212A1 (en) 2004-02-10 2005-08-25 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sina)
WO2005098049A2 (en) 2004-03-25 2005-10-20 California Institute Of Technology Hybridization chain reaction
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
AU2005244258B2 (en) 2004-04-09 2010-07-01 Monsanto Technology Llc Compositions and methods for control of insect infestations in plants
JP2007536937A (ja) * 2004-05-12 2007-12-20 カメル・カリーリ 霊長類ポリオーマウイルス遺伝子のｓｉＲＮＡ干渉用組成物および方法
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
WO2005115481A2 (en) 2004-05-27 2005-12-08 Alnylam Pharmaceuticals, Inc. Nuclease resistant double-stranded ribonucleic acid
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
TWI386225B (zh) * 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
CN101124339A (zh) * 2004-12-30 2008-02-13 托德·M·豪泽 使用自我保护寡核苷酸调节基因表达的组合物和方法
EP2584033A1 (en) 2005-01-12 2013-04-24 Monsanto Technology LLC Genes and uses for plant improvement
US7727721B2 (en) 2005-03-08 2010-06-01 California Institute Of Technology Hybridization chain reaction amplification for in situ imaging
US8034994B2 (en) 2005-04-19 2011-10-11 Basf Plant Science Gmbh Starchy-endosperm and/or germinating embryo-specific expression in mono-cotyledonous plants
JPWO2006132204A1 (ja) 2005-06-06 2009-01-08 アンジェスＭｇ株式会社 転写因子デコイ
US9297036B2 (en) 2005-07-01 2016-03-29 Agilent Technologies, Inc Nucleic acid probes for analysis of small RNAs and other polynucleotides
ES2557512T3 (es) 2005-09-16 2016-01-26 Devgen N.V. Métodos basados en plantas transgénicas para plagas de plantas usando ARNi
EP2426208B1 (en) 2005-09-16 2016-11-09 Monsanto Technology, LLC Methods for genetic control of insect infestations in plants and compositions thereof
US8933042B2 (en) 2005-09-16 2015-01-13 Devgen Nv Methods for controlling pests using RNAi
US7960357B2 (en) * 2005-10-07 2011-06-14 California Institute Of Technology PKR activation via hybridization chain reaction
EP1978096A1 (en) 2005-12-22 2008-10-08 Genomidea Inc Novel oligonucleotide and nf-kappa b decoy comprising the same
KR20080094918A (ko) 2006-01-17 2008-10-27 바이오렉스 쎄라퓨틱스, 인코포레이티드 식물에서 ｎ-글리칸의 인간화 및 최적화 조성물 및 방법
US7754475B2 (en) * 2006-01-25 2010-07-13 Agilent Technologies, Inc. Nucleic acid probes and microarrays for analysis of polynucleotides
EP1984499B1 (en) 2006-01-27 2015-05-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
CN101501199B (zh) 2006-02-10 2016-11-09 孟山都技术有限公司 用于控制植物寄生线虫的靶基因的鉴定和用途
CA2637363C (en) 2006-02-13 2016-04-05 Monsanto Technology Llc Selecting and stabilizing dsrna constructs
US20100184209A1 (en) 2006-02-17 2010-07-22 Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
US8158598B2 (en) * 2006-05-05 2012-04-17 Isis Pharmaceuticals, Inc. Compositions and their uses directed to PTPR alpha
CN101195821A (zh) 2006-12-04 2008-06-11 中国科学院上海生命科学研究院 利用RNAi技术改良植物抗虫性的方法
EP2641971A1 (en) 2007-01-29 2013-09-25 Isis Pharmaceuticals, Inc. Compounds and methods for modulating protein expression
KR20090119910A (ko) 2007-02-16 2009-11-20 바스프 플랜트 사이언스 게엠베하 외떡잎 식물에서 배-특이적 발현의 조절을 위한 핵산 서열
US8318921B2 (en) 2007-03-01 2012-11-27 California Institute Of Technology Triggered RNAi
EP2155770B1 (en) 2007-05-16 2013-10-16 California Institute of Technology A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways
WO2009023819A2 (en) * 2007-08-15 2009-02-19 Idera Pharmaceuticals, Inc. Toll like receptor modulators
US8497364B2 (en) 2008-02-27 2013-07-30 California Institute Of Technology Triggered RNAi
US8241854B2 (en) 2008-05-22 2012-08-14 California Institute Of Technology Triggered RNAi
CA2727285A1 (en) * 2008-06-11 2009-12-17 Bionucleon S.R.L. Inhibition of hrp-3 using modified oligonucleotides
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
JP2012523850A (ja) 2009-04-20 2012-10-11 モンサント テクノロジー エルエルシー 植物中の複数ウイルス抵抗性
DK2558578T3 (en) 2010-04-13 2016-01-25 Life Technologies Corp CONFIGURATIONS AND METHODS FOR INHIBITION OF nucleic acid function
US8658780B2 (en) 2010-05-18 2014-02-25 California Institute Of Technology Triggered covalent probes for imaging and silencing genetic expression
US9834439B2 (en) 2010-07-20 2017-12-05 California Institute Of Technology Biomolecular self-assembly
US8962241B2 (en) 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
US8877438B2 (en) 2010-07-20 2014-11-04 California Institute Of Technology Self-assembled polynucleotide structure
WO2012027206A1 (en) 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
CN103403164A (zh) 2010-12-30 2013-11-20 陶氏益农公司 靶向rho1小gtp结合蛋白并赋予对鞘翅目有害生物的抗性的核酸分子
US8987552B2 (en) 2010-12-30 2015-03-24 Dow Agrosciences, Llc. Nucleic acid molecules that target the vacuolar ATPase H subunit and confer resistance to coleopteran pests
CN103403162A (zh) 2010-12-30 2013-11-20 陶氏益农公司 赋予对鞘翅目有害生物的抗性的核酸分子
UY33854A (es) 2010-12-30 2012-07-31 Dow Agrosciences Llc Moléculas de ácido nucleico que se dirigen a la subunidad c de la atpasa vacuolar y confieren resistencia a las plagas de coleópteros
CA2895077A1 (en) 2011-12-12 2013-06-20 Beverly Packard In vivo delivery of oligonucleotides
US9688983B2 (en) 2012-12-20 2017-06-27 Dow Agrosciences Llc Nucleic acid molecules that confer resistance to coleopteran pests
EP2810952A1 (en) 2013-06-03 2014-12-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel pest control methods
US9856472B2 (en) 2013-07-01 2018-01-02 California Institute Of Technology Small conditional RNAs
AU2014306416B2 (en) * 2013-08-16 2021-02-25 Translate Bio Ma, Inc. Compositions and methods for modulating RNA
BR102014031844A2 (pt) 2013-12-20 2015-10-06 Dow Agrosciences Llc ras oposto (rop) e moléculas de ácido nucleico relacionadas que conferem resistência a pragas de coleópteros e hemípteros
WO2015095750A1 (en) 2013-12-20 2015-06-25 Dow Agrosciences Llc Rnapii-140 nucleic acid molecules that confer resistance to coleopteran pests
MX366975B (es) 2014-03-12 2019-08-01 Univ Sydney Produccion de arn en plantas superiores.
RU2016146483A (ru) 2014-05-07 2018-06-09 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Молекулы нуклеиновой кислоты dre4, сообщающие резистентность к жесткокрылым вредителям
CN105087554B (zh) * 2014-05-14 2017-09-22 武汉大学 Dna磷硫酰化修饰基因簇
KR102290205B1 (ko) 2014-06-04 2021-08-20 엑시큐어, 인크. 예방 또는 치료 용도를 위한 리포솜성 구형 핵산에 의한 면역 조절인자의 다가 전달
US20160194658A1 (en) 2014-12-22 2016-07-07 Dow Agrosciences Llc Nucampholin nucleic acid molecules to control coleopteran insect pests
WO2016130943A1 (en) 2015-02-13 2016-08-18 Rana Therapeutics, Inc. Hybrid oligonucleotides and uses thereof
US20160264991A1 (en) 2015-03-13 2016-09-15 Dow Agrosciences Llc Rna polymerase i1 nucleic acid molecules to control insect pests
US20180105832A1 (en) 2015-04-13 2018-04-19 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Novel aflatoxin and fungal infection control methods
BR102016012010A2 (pt) 2015-05-29 2020-03-24 Dow Agrosciences Llc Molécula de ácido nucleico, de ácido ribonucleico (rna) e de ácido ribonucleico de filamento duplo (dsrna), usos de célula, planta e semente, produto primário, bem como métodos para controlar uma população de pragas coleópteras e/ou hemípteras, para melhorar o rendimento de uma cultura, e para produzir uma célula vegetal transgênica e uma planta transgênica
AU2016337355B2 (en) 2015-10-12 2019-09-26 Dow Agrosciences Llc WupA nucleic acid molecules that confer resistance to coleopteran and hemipteran pests
US10329581B2 (en) 2015-12-18 2019-06-25 Dow Agrosciences Llc Ribosomal protein L40 (RPL40) nucleic acid molecules that confer resistance to coleopteran and hemipteran pests
EP3943613A1 (en) 2016-07-05 2022-01-26 California Institute of Technology Fractional initiator hybridization chain reaction
IL264831B (en) 2016-08-30 2022-09-01 California Inst Of Techn Immunohistochemistry by hybridization chain reaction
EP3538657A4 (en) 2016-11-10 2021-02-17 Dow AgroSciences LLC CYTOCHROME B (CYTB) NUCLEIC ACID MOLECULES THAT REGULATE PATHOGENS
EP3342780A1 (en) 2016-12-30 2018-07-04 Dow AgroSciences LLC Pre-mrna processing factor 8 (prp8) nucleic acid molecules to control insect pests
WO2018201090A1 (en) * 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
EP3825408A1 (en) 2019-11-19 2021-05-26 FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. Methods of multi-species insect pest control
EP4284925A1 (en) 2021-01-26 2023-12-06 California Institute of Technology Allosteric conditional guide rnas for cell-selective regulation of crispr/cas

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3256539B2 (ja) * 1990-08-28 2002-02-12 エポック・ファーマシューティカルズ・インコーポレイテッド 連結分子を介する３’―尾分子付オリゴヌクレオチドの固体支持体合成

Also Published As

Publication number Publication date
FI946201A (sv) 1994-12-30
PL307025A1 (en) 1995-05-02
CA2139319A1 (en) 1994-01-20
KR950702626A (ko) 1995-07-29
CZ333294A3 (en) 1995-07-12
HUT69981A (en) 1995-09-28
PL172710B1 (pl) 1997-11-28
DE69321122D1 (de) 1998-10-22
HU9403788D0 (en) 1995-02-28
AU4770093A (en) 1994-01-31
JPH08501928A (ja) 1996-03-05
NZ255028A (en) 1997-03-24
EP0649467B1 (en) 1998-09-16
WO1994001550A1 (en) 1994-01-20
EP0649467A1 (en) 1995-04-26
RU94046425A (ru) 1997-03-20
ATE171210T1 (de) 1998-10-15

Similar Documents

Publication Publication Date Title
FI946201A0 (sv) Självstabiliserade oligonukleotider som terapeutiska medel
ATE138384T1 (de) Olionukleotidalkylphosphonate und - phosphonothioate
BR9306775A (pt) Fosforotioato e/ou fosforoditioato de oligonucleotídeo híbrido formulação farmacéutica terapéutica e processo para inibir a expressão genética de um vírus organismo patogénico ou gene celular
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
ATE162198T1 (de) Oligonukleotid alkylphosphonothiate
ZA200304500B (en) Method for inhibiting the expression of a target gene and medicament for treating a tumor disease.
WO1994024144A3 (en) Enhanced triple-helix and double-helix formation with oligomers containing modified purines
ATE216705T1 (de) Antisense-oligonukleotidmodulation der raf- genexpression
CA2088917A1 (en) Therapeutic ribozyme compositions
DE69431164D1 (de) Gegenläufige oligonukleotide mit hemmender wirkung auf tumorbildung
WO2000014217A3 (en) G-motif oligonucleotides and uses thereof
ATE174599T1 (de) Bindungskompetente oligomere, die 2',5'-bindungen enthalten
DE69934227D1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
FR2790757B1 (fr) Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
EP0775745A3 (en) Cathepsin G-inhibiting aptamers
SE9503117L (sv) Ny användning av padlockprober
WO1999028439A3 (fr) Erythrovirus et ses applications
ES2112062T3 (es) Oligonucleotidos con actividad anti-citomegalovirus.
HUP9702251A2 (hu) Többfunkciós ligandumrendszer nukleinsavak sejtspecifikus bejuttatására
WO2003031459A3 (de) Modulation der expression stat-1-abhängiger gene
NO945020L (no) Selv-stabiliserende oligonukleotider som terapeutiske midler
ATE318617T1 (de) Synthetische oligonukleotide als erythroid differenzierungserreger
Abdula Silencing the code

Legal Events

Date Code Title Description
FD Application lapsed